作为脂质纳米颗粒配方的聚乙烯糖醇替代品
Dwain George van Zyl1, Livia Palmerston Mendes1, Raphaela Patricia Semper1
1CureVac SE, Tübingen, Germany.
Frontiers in drug delivery
|August 21, 2025
概括
脂质纳米颗粒中的聚乙烯糖醇 (PEG) 可能具有免疫性. 聚-2-甲基-2-zoline) (PMOZ) 是一个有前途的PEG替代品,可以增强T细胞的反应,同时保持mRNA治疗药物的抗体产生.
科学领域:
- 生物技术和制药科学
- 纳米医学和药物输送系统
- 免疫学和疫苗学
背景情况:
- 脂质纳米颗粒 (LNP) 对于mRNA传递至关重要,聚乙烯糖醇 (PEG) 是稳定的标准成分.
- 越来越多的证据表明PEG具有免疫性,需要探索下一代mRNA疗法的替代聚合物.
- 作为LNP配方中PEG的潜在替代品,PMOZ正在研究中.
研究的目的:
- 评估PMOZ作为基于LNP的mRNA输送系统中的PEG替代品的适用性.
- 将含有PMOZ的LNP与传统的基于PEG的LNP的特性和生物活性进行比较.
- 评估PMOZ百分比和密度对传染效率和免疫反应的影响.
主要方法:
- 具有不同百分比和密度的PMOZ的LNP的配方.
- 对于mRNA传递效率的PMOZ-LNP与PEG-LNP的比较
- 在体内评估PMOZ-LNP诱导的抗原特异性T细胞和抗体反应.
主要成果:
- 降低PMOZ百分比提高了传染效率和免疫刺激潜力.
- 减少PMOZ密度增强了体内特异性T细胞反应,而不是抗体反应.
- 与PEG- LNP相比,PMOZ- LNP诱导了更高的中和抗体标位,而PEG- LNP则引起了更强的CD8+T细胞反应.
结论:
- 在LNP配方中,PMOZ具有作为PEG可行的替代品的潜力.
- 定制PMOZ含量和密度可以调节免疫反应,为疫苗开发提供策略.
- 基于PMOZ的LNP的进一步开发可能会带来改善的mRNA疗法,并减少免疫性问题.
更多相关视频
相关概念视频
00:59Nonlinear Pharmacokinetics: Drug Elimination for IV Bolus Injection
557
In pharmacokinetics, the elimination rate of a drug following a capacity-limited model is primarily controlled by two parameters: Vmax and KM. These parameters are crucial in how the drug behaves inside the body after administration.
Following the administration of a single intravenous (IV) bolus injection, we can determine the concentration of the drug in the plasma at any given time. This calculation is achieved using a specific equation that integrates the values of Vmax and KM.
We can also...
Following the administration of a single intravenous (IV) bolus injection, we can determine the concentration of the drug in the plasma at any given time. This calculation is achieved using a specific equation that integrates the values of Vmax and KM.
We can also...
557
01:26Pharmaceutical Equivalents
274
As defined by regulatory standards, pharmaceutical equivalents require generic drug products to have identical dosage forms and chemically identical active pharmaceutical ingredients (APIs). They must adhere to compendial or applicable standards for potency, content uniformity, disintegration times, and dissolution rates. In the case of modified-release dosage forms, variations in drug content are permissible as long as the delivered amount remains consistent with the innovator drug product.
274
01:22Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence
259
Generic intravenous (IV) drugs are considered bioequivalent to their branded counterparts due to their 100% bioavailability upon administration. However, variations in stability among different drug products can significantly influence their therapeutic performance, even if they are pharmaceutically equivalent.Cefuroxime, a prophylactic antimicrobial, is often used as a single-dose IV injection for patients undergoing coronary artery bypass grafting surgery. A 3 g dose typically provides...
259
01:19Pharmaceutical Alternatives: Excipients and Impurities-Related Therapeutic Nonequivalence
241
Pharmaceutical products contain more than just the active drug; they also contain various excipients such as binders, solubilizers, stabilizers, preservatives, and other elements. In some cases, impurities or contaminants might be present. Traditionally, quality control in pharmaceuticals has primarily focused on the analysis of the active drug, often overlooking the impact of these additional components. The recent issue with heparin contamination by over-sulfated chondroitin sulfate, a...
241
01:27Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence
226
Changes in polymorphic forms can significantly influence the bioavailability of poorly soluble drugs. Although the FDA defines pharmaceutical equivalence based on having the same active ingredient, dosage form, and route of administration, it does not automatically disqualify products with different polymorphic forms. This means two products with different polymorphs can still be deemed pharmaceutically equivalent. However, polymorphic differences can affect properties like wettability,...
226
01:24Glucagon-like Receptor Agonists
1.3K
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
1.3K